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Abstract
Objectives To provide an automated classification method for degenerative parkinsonian syndromes (PS) based on semi-
quantitative 123I-FP-CIT SPECT striatal indices and support-vector-machine (SVM) analysis.
Methods 123I-FP-CIT SPECT was performed at a single-center level on 370 individuals with PS, including 280 patients with 
Parkinson’s disease (PD), 21 with multiple system atrophy-parkinsonian type (MSA-P), 41 with progressive supranuclear 
palsy (PSP) and 28 with corticobasal syndrome (CBS) (mean age 70.3 years, 47% female, mean disease duration at scan 
1.4 year), as well as 208 age- and gender-matched control subjects. Striatal volumes-of-interest (VOIs) uptake, VOIs asym-
metry indices (AIs) and caudate/putamen (C/P) ratio were used as input for SVM individual classification using fivefold 
cross-validation.
Results Univariate analyses showed significantly lower VOIs uptake, higher striatal AI and C/P ratio for each PS in com-
parison to controls (all p < 0.001). Among PS, higher degree of striatal impairment was observed in MSA-P and PSP, while 
CBS showed moderate uptake reduction and higher AI. Binary SVM classification showed 92.9% accuracy in distinguishing 
PS from controls. Classification based on each binary combination of PS ranged 62.9–83.7% accuracy with the most satis-
factory results when separating CBS from the other PS. Sensitivity and specificity values were high and balanced ranging 
from 60 to 80% for all analyses with > 70% accuracy. Overall, striatal AI and C/P ratio on the more affected side had the 
highest weighting factors.
Conclusion Semiquantitative 123I-FP-CIT SPECT striatal evaluation combined with SVM represents a promising approach 
to disentangle PD from non-degenerative conditions and from atypical PS at the early stage.
Keywords Parkinson’s disease · Degenerative parkinsonism · SPECT · Classification
Introduction
Parkinson Disease (PD) is the most common neurodegen-
erative movement disorder in the general population and 
accounts for 65% of all parkinsonian syndromes (PS) [1]. It 
is characterized by progressive akinesia in association with 
rest tremor and muscular rigidity as well as an excellent 
response to levodopa therapy [2]. Clinical diagnosis is not 
always straightforward and distinction from atypical parkin-
sonian syndromes (APS) can be particularly challenging in 
the early phase. In fact, autopsy-based studies have shown 
that diagnostic accuracy for PD does not exceed 79.6% even 
when clinical diagnosis is performed by movement disorders 
experts, or 82.7% when using stringent clinical criteria for 
PD [3]. Misclassification involves other degenerative con-
ditions—i.e., multiple system atrophy (MSA), progressive 
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supranuclear palsy (PSP) and corticobasal degeneration 
(CBD). Compared to PD, APS are characterized by addi-
tional clinical features besides parkinsonism (cerebellar or 
pyramidal signs, postural instability or apraxia), a moderate 
or transient response to levodopa and a worse prognosis with 
a mean life expectancy of 7–10 years from disease onset [4, 
5]. The issue of PD clinical misdiagnosis has virtually not 
improved over the last 25 years, and various biomarkers, 
notably structural and metabolic imaging, have been exam-
ined as potential aids to clinical diagnosis and, to a lesser 
extent, to separate the different forms of degenerative PS 
[6]. As yet, however, only a few of the proposed biomarkers 
have proved robust enough to be included in the new MDS 
criteria for PD—olfactory loss and cardiac sympathetic den-
ervation as supportive criteria, and a normal presynaptic 
dopaminergic system as exclusion criterion [2].
Presynaptic dopaminergic pathways integrity can be 
assessed with various compounds, 123I-FP-CIT (ioflupane) 
being the most widely used due to its fast kinetics, selectivity 
to dopamine transporters (DaT), SPECT scan availability, 
and its binding not being affected by concurrent dopaminer-
gic treatment [7]. While visual and semiquantitative assess-
ments have shown excellent sensitivity and specificity (resp. 
97 and 100%) in differentiating early clinically diagnosed 
PD subjects (showing a reduced striatal uptake) from non-
degenerative cases, similar observations could not be drawn 
for the distinction of PD and APS [8–11]. In fact, there is 
a large consensus among experts that DaT SPECT is not 
able to separate PD from APS, although this assumption 
has not been extensively studied. In fact, recent publications 
have shown data partly challenging this consensus. At the 
group level, PD subjects usually harbor an asymmetric ros-
trocaudal progression of DaT denervation, with a preserva-
tion of caudate nucleus uptake in the early phase, whereas 
MSA-parkinsonism (MSA-P) and PSP usually show a more 
global uptake impairment [12]. In patients with corticobasal 
syndrome (CBS), a highly asymmetric and moderate uptake 
alteration has been described [13], with several cases pre-
senting a virtually normal SPECT [8, 14]. However, indi-
vidual detection of subjects with degenerative PS based on 
molecular imaging remains elusive.
Support vector machine (SVM) is a widely used pat-
tern-recognition method that learns to assign labels to 
feature vectors [15] and has been used increasingly for 
automated classification in a variety of medical applica-
tions (for a review, see [16]). SVMs have been applied 
to distinguish PD from controls (CTL) or APS based on 
usually complex and time-consuming processing of vari-
ous imaging techniques—e.g., DaT SPECT, postsynaptic 
dopamine PET, diffusion tensor imaging (DTI) or voxel-
based morphometry (VBM) MRI imaging with accuracies 
ranging from 70 to 100% [17–25]. Thanks to multivariate 
pattern-recognition analyses of 123I-FP-CIT SPECT, we 
recently observed a differential pattern of uptake alteration 
between PD and APS; i.e., a more severe caudate nucleus 
impairment in MSA and PSP, and a relative preservation 
of putaminal uptake in CBS compared to PD [26].
We here propose to reappraise the issue of distinguish-
ing the various forms of degenerative PS by means of 
an SVM classification solely based on semiquantitative 
123I-FP-CIT SPECT striatal parameters, the most com-
monly used output to support diagnosis in clinical prac-
tice, obtained from a large, single-center cohort of subjects 
with idiopathic PD, MSA-P, PSP and CBS in the early 




The present study was conducted in compliance with the 
declaration of Helsinki and was approved by the canton of 
Geneva Ethics Committee (CER 12-006R). As a retrospec-
tive study evaluating SPECT imaging performed in the diag-
nostic setting, written consent from subjects was waived. 
123I-FP-CIT SPECT was performed between October 2003 
and October 2016, and the following clinical data were col-
lected: sex, diagnosis, age at scan, disease duration at scan. 
Whenever a subject had two or several scans, only the first 
one was considered. Besides, only SPECT scans acquired on 
the same scanner and with the same protocol were included. 
All subjects with sporadic and idiopathic PD, MSA-P, PSP 
and CBS were classified according to the most recent clini-
cal diagnostic criteria [2, 4, 5, 27], with a disease dura-
tion < 3 years at scan and age > 40 years at disease presenta-
tion to exclude potentially genetic young-onset PD cases. 
Disease duration at scan was considered as the time between 
onset of motor symptoms and performing the SPECT scan. 
In addition, we included a CTL group, i.e., subjects with 
non-degenerative parkinsonism or tremor [essential tremor 
(ET), drug-induced parkinsonism (DIP) and psychogenic 
parkinsonism (PP)] associated with preserved DaT uptake 
based on both visual and semiquantitative assessments, and 
with identical restrictions regarding age (> 40 years) and 
disease duration at scan (< 3 years).
SPECT imaging acquisition and reconstruction
Details on the acquisition of SPECT imaging are available 
in Ref. [28]. Illustrative examples of typical patterns of DaT 
SPECT alterations in patients with PD, MSA, PSP and CBD, 
and of CTL subjects are shown in Fig. 1.
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Semiquantitative SPECT assessment
The BRASS™ automated functional brain analysis software 
[29] was used to extract semiquantitative uptake values for 
the following volumes-of-interest (VOIs): right and left cau-
date nucleus (C), putamen (P), striatum (S) as well as occipi-
tal lobe which was used as the reference. Uptake values 
regarding S were obtained by geometrical interpolation with 
the following formula: uptake (S) = (uptake (C) × volume
(C) + uptake (P) × volume (P))∕volume (S) with volume 
based on the Talairach atlas (in voxels). Therefore, the formula 
used to calculate S uptake was ((C × 524) + (P × 689))/1213. 
Asymmetry indices (AI) for each striatal VOI (C-AI, S-AI and 
P-AI) and C/P ratio on the most and least affected side have 
Fig. 1  Illustrative examples of 123I-FP-CIT SPECT scan images (axial 
slices) performed within a year after disease onset in patients with 
autopsy-proven PD (M, 65 years old), MSA-P (M, 67), PSP (F, 60) 
and CBS (F, 67), compared to a 65-year-old control female patient 
with dystonic tremor (CTL)
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been calculated accordingly. For the following analyses, we 
used C, P and S uptake as well as C/P ratio considering 
the most and least affected side, based on semiquantitative 
uptake values.
Support‑vector‑machine classification analysis
Due to the presence of strongly imbalanced classes as 
reflected by disease prevalence (notably PD vs. each APS 
subtype), the R-package “ROSE” (Version i2015) was 
applied to balance the dataset for binary classification using 
a smoothed bootstrap approach [30, 31]. The classifica-
tion analysis was then performed using the “Classification 
Learner App” (MATLAB 2016b, MathWorks). A linear 
SVM classifier was applied to learn a discriminant function 
that would optimally separate the respective class labels. 
Each training model was based on the 123I-FP-CIT SPECT 
uptake of a set fourteen features: uptake on the more affected 
side (more), less affected side (less), mean uptake value 
(mean), and AI for each ROI, i.e., S, C and P; as well as the 
C/P ratio on the more affected [C/P ratio (more)] and the less 
affected side [C/P ratio (less)]. The classes included in the 
classification procedure were chosen according to clinical 
decision-making.
Once the classifier trained, the code was exported to the 
MATLAB workspace and run using a custom-made script 
to extract the SVM weights (betas). For each model (i.e., 
all PS vs. CTL; PD vs. APS; each PS vs other PS; and all 
binary combination between PS), classification accuracy 
(Acc), specificity (Sp) and sensitivity (Sn) as well as the 
receiver operating characteristics-area under curve (ROC-
AUC) were calculated using fivefold cross-validation. Acc 
measures the probability that a random patient would be 
correctly identified by the classifier. The statistical signifi-
cance of the Acc measures was obtained by establishing its 
null distribution under random permutations (1000 times) 
of the class labels. Finally, we minimized the false-positive 
rate for APS by determining a high specificity of 0.95 for PD 
classification against other PS. We reported AUC measures 
as they reflect classification performance across every pos-
sible specificity–sensitivity trade-off and are not sensitive to 
sample distribution. A flowchart summarizing the different 
steps of subjects’ inclusion and SVM processing is available 
as Fig. 2.
Statistics
Statistical analysis was performed with Stata software 
Version 14.2 (College Station, TX). Assessment of dis-
tribution for continuous variables was performed with 
Shapiro–Wilk test and visualization of histogram plots, 
followed by ANOVA or Kruskal–Wallis (KW) tests 
accordingly, and t test or Mann–Whitney U (MWU) 
test for two-group post hoc comparisons. Statistical 
significance was considered if p < 0.05. When assess-
ing semiquantitative uptake between CTL and each PS, 
Fig. 2  Flowchart of the study, summarizing patient inclusion, image processing and SVM analysis
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and among PD and APS, we used Bonferroni correction 
for each dependent variable (10 pairwise comparisons 
so p < 0.05/10 = 0.005). Values are usually reported as 
mean ± standard deviation (SD) (range). We also per-
formed ROC curves with determination of cut-off points 
using the most significant univariate predictor and 
Youden index (best specificity/sensitivity trade-off) to 
design a tentative flowchart.
Results
Patients’ baseline characteristics
1363 subjects were scanned in our institution with the 
same SPECT acquisition protocol during the 13-year 
study period, among which 370 participants presented 
with a degenerative PS and fulfilled inclusion criteria 
(age ≥ 40, disease duration ≤ 3 years): 280 PD, 21 MSA-P, 
41 PSP and 28 CBS subjects. As previously shown by our 
group, MSA-P and MSA-C have a very distinct dopamine 
SPECT pattern [32], so we decided not to include MSA-C 
subjects in further analysis as the MSA-C group was very 
small (n = 5). A total of 208 age-matched CTL subjects 
were also included. Mean follow-up was 4.4 ± 2.9 years 
(range 0.3–11.3). Baseline characteristics and VOIs 
uptake values for each group are available in Table 1.
123I‑FP‑CIT SPECT semiquantitative results
As expected, univariate analyses showed that, in comparison 
to CTL, each PS group (PD, MSA-P, PSP and CBS) had 
higher S-AI and C/P (more) (p < 0.001, MWU test) and sig-
nificantly lower mean S, C and P uptake values (p < 0.0001) 
when using age-adjusted previously established local refer-
ence limits [28] (Fig. 3).
Among degenerative conditions, head-to-head com-
parisons showed that PD subjects exhibited significantly 
higher mean uptake in the S, C and P compared to MSA-P 
(all p < 0.002) and PSP (all p < 0.005) and lower P uptake 
compared to CBS (p < 0.005). CBS subjects also exhibited 
higher S and P uptake compared to MSA-P (all p < 0.0005) 
and to PSP (all p < 0.001).
Regarding CBS, S-AI was significantly higher than for 
PSP (p = 0.0004) and C/P ratio (more) was lower than for 
all other PS (all p < 0.005).
Linear SVM binary classification
Binary classification of all PS versus Controls showed excel-
lent results (Sp 96.7%, Sn 89.5%, Acc 92.9%), with S-AI, S 
uptake and C/P ratio (more) being the strongest predictors 
(Table 2).
Binary classification of each combination of PS showed 
the best results when separating CBS from the other con-
ditions—with Acc 83.7% against MSA-P, Acc 73.1% 
against PD and Acc 73.9% vs PSP. S-AI was also one of 
Table 1  Baseline clinical characteristics of degenerative parkinsonism and control groups
Mean (left + right) VOIs uptake, C/P ratio and striatal AI are also shown. Results are expressed Mean ± SD (range)
Statistical analysis: aKruskall Wallis test, bChi-squared test
PD MSA-P PSP CBS Control Pval Pval




Age (years) 69.8 ± 10.8 
(42–92)
69.0 ± 11.0 
(43–86)
72.7 ± 7.6 
(44–85)
73.6 ± 7.8 
(56–85)





1.3 ± 0.8 (0–3) 1.5 ± 0.8 (0.5–3) 1.6 ± 0.9 (0.3–3) 1.6 ± 0.7 (0.5–3) NA 0.09a
Male/female 
ratio
1.12 (148/132) 1.1 (11/10) 1.05 (21/20) 1.15 (15/13) 0.66 (83/125) 0.07b 0.99b
S uptake 1.79 ± 0.64 
(0.24–4.14)
1.35 ± 0.56 
(0.49–3.17)
1.38 ± 0.60 
(0.39–2.82)
1.96 ± 0.76 
(0.20–4.04)
3.16 ± 0.55 
(1.78–5.33)
All < 0.005a
C uptake 2.25 ± 0.71 
(0.31–4.63)
1.80 ± 0.61 
(0.80–3.56)
1.70 ± 0.64 
(0.48–3.17)
2.20 ± 0.84 
(0.25–4.24)
3.37 ± 0.62 
(1.55–6.05)
P uptake 1.44 ± 0.64 
(0.19–3.76)
1.01 ± 0.54 
(0.14–2.88)
1.13 ± 0.60 
(0.17–2.59)
1.78 ± 0.75 
(0.17–3.89)
3.01 ± 0.54 
(1.44–4.79)
C/P ratio (most 
affected side)
1.86 ± 0.67 
(0.47–6.73)
2.35 ± 1.37 
(1.26–6.79)
1.72 ± 0.46 
(0.79–2.82)
1.37 ± 0.41 
(0.72–2.65)
1.13 ± 0.15 
(0.71–1.75)
Striatal AI 19.8 ± 14.8 
(0.4–73.4)
19.7 ± 18.0 
(0.4–63.2)
13.7 ± 10.9 
(0.1–44.5)
31.3 ± 29.4 
(1.6–150.6)
4.8 ± 3.7 
(0.0–19.2)
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the strongest predictors. Correct classification of PD vs 
MSA-P and PSP revealed less robust but still satisfactory 
results, with Acc 63.5% and 64.8%, respectively.
When assessing binary classification of each PS vs all 
other PS, we observed the best results when classifying 
all other PS from MSA-P (Acc 74.4% with Sp 77.1% and 
Sn 71.4%) and from CBS (Acc 76.7% with Sp 83.3% and 
Sn 69.1%). On the other hand, correct classification was 
modest for PD (Acc 58.4%) and PSP (60%).
Designing a tentative diagnostic flowchart
To construct a simple diagnostic flowchart that could 
be used by other centers, the most informative outcomes 
obtained from the univariate semiquantitative BRASS analy-
sis (Table 1) were converted into percentages, with 100% 
corresponding to the reference limits based on a previous 
work [28]. As shown on Fig. 4, a step-by-step procedure 
may allow to best separate (1) CTL from PS using P (more) 
Fig. 3  Violin plots of repre-
sentative striatal outcomes 
[C(more), P(more), S-AI, 
C/P(more)] for the different 
groups included in the study. 
Outcome values are shown on a 
logarithmic scale
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(p < 0.0001); (2) PD and CBS from MSA-P and PSP patients 
using S (less) (p < 0.0001); (3) PD and CBS by means of 
the C/P ratio (more) (p < 0.0001), and (4) MSA-P and PSP 
also with C/P ratio (more) (p < 0.03). Density plots of these 
particularly discriminant outcomes were added at each step 
to illustrate how groups are set apart.
Discussion
We here presented an SVM analysis aiming at separating 
degenerative parkinsonisms strictly based on their semiquan-
titative 123I-FP-CIT SPECT uptake values and related com-
bined parameters. This analysis was tested on highly homo-
geneous data collected from a large, single-center cohort of 
subjects with well-characterized PS scanned with identical 
acquisition and processing imaging protocol.
Univariate statistics of semiquantitative evaluation 
confirm previous findings [33] of significantly decreased 
uptake in all forms of PS compared to subjects with 
non-degenerative conditions, namely lower striatal uptake, 
as well as higher AI and C/P ratio.
Thanks to previously established local age-dependent ref-
erence limits for striatal VOIs uptake, AIs and C/P ratio [28], 
we also confirmed that CBS subjects have a relative preser-
vation of presynaptic dopamine transporters as they exhib-
ited higher P uptake in comparison to PD (p < 0.005) and 
higher P, C and S uptake compared to MSA-P (p < 0.0005) 
and PSP (p < 0.001). In addition, we found significantly 
higher S-AI in the CBS group in comparison to PSP and 
lower C/P ratio than PD, MSA-P and PSP (all p < 0.005) 
[34]. PD subjects had an intermediate degree of striatal 
impairment with higher uptake ratio in all striatal VOIs 
compared to MSA-P and PSP. These results are in keeping 
with previous works [35].
We here report a striking SVM classification accuracy 
(92.9%, AUC 0.97) in disentangling PS from CTL, with a 
major contribution of both uptake and asymmetry param-
eters. Previous SVM studies have already attempted to 
separate PD from CTL subjects using 123I-FP-CIT SPECT 
Table 2  Classification 
performance of the 123I-FP-CIT 
SPECT SVM analysis
Sp (%) Sn (%) Acc (%) AUC Highest beta weights p value
Binary classification of PS vs CTL




Binary classifications of each combination of two PS



























Binary classifications of each PS vs all other PS




 MSA-P vs non-MSA-P 77.1 71.4 74.4 0.78 C/P ratio (more)
C-AI
0.002
 PSP vs non-PSP 54.2 66.7 60 0.58 C/P ratio (more)
S-AI
0.06
 CBS vs non-CBS 83.3 69.1 76.7 0.88 P (mean)
S-AI
 < 0.001
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striatal uptake and length/volume [36] or complex SPECT 
and biological data (including serum and CSF) from the 
Parkinson Progressive Markers Initiative cohort [19] with 
Acc 96–97%.
Furthermore, binary classification of each combination of 
PS allowed Acc 62.9–83.7%, with the best results obtained 
when separating CBS from each other PS. Considering 
the discussion above, these findings are not surprising, 
as it is well recognized that CBS harbors a specific pat-
tern of impairment—i.e., relative striatal uptake preserva-
tion and moderate-to-high AI, especially in comparison 
to MSA-P (Acc in the present study 83.7%) and PSP (Acc 
73.9%), which in turn exhibit a more severe and symmetri-
cal impairment of striatal uptake. Conversely, we observed 
Fig. 4  A tentative diagnostic flowchart using relevant outcomes 
[P(more), S(less) uptakes and C/P ratio on the more affected side] 
from the semiquantitative analysis to separate CTL and the various 
PS (PD, MSA-P, PSP or CBS) groups according to reference limits 
expressed as percentages of normal values. Selective density plots are 
shown at each step
1779Journal of Neurology (2019) 266:1771–1781 
1 3
an intermediate level of uptake and AI in PD, which could 
explain why head-to-head classification accuracy of PD vs 
other PS is lower (63.5–73.1%).
In previous studies, Haller et al. observed 97% accuracy 
for the classification of PD subjects vs. a heterogeneous 
group of other PS, including mainly MSA, but also vas-
cular parkinsonism, dementia with Lewy bodies and psy-
chogenic parkinsonism, using fractional anisotropy DTI. 
Thanks to MRI atlas-based volumetry, Huppertz et  al. 
found balanced accuracies superior to 80% for the distinc-
tion of PD from PSP and MSA, whereas a VBM study of 
Focke [17] found balanced accuracies superior to 80% for 
the distinction of PD from PSP and MSA, whereas a VBM 
study of Focke et al. showed 87.1% and 71.9% accuracies 
in separating PD from PSP and MSA, respectively [22]. 
Cherubini et al. were able to obtain 100% correct classi-
fication in classifying PD and PSP based on white matter 
atrophy. In addition, postsynaptic D2/D3 [20] were able to 
obtain 100% correct classification in classifying PD and 
PSP based on white matter atrophy. Moreover, postsynaptic 
D2/D3 18F-desmethoxyfallypride (DMFP) PET SVM has 
shown 70–75% accuracy for the distinction of PD from 
MSA and PSP) [18]. Although these efforts are commend-
able, they also have inherent limitations—e.g., small sam-
ple sizes [20, 22], the debatable choice of merging several 
APS groups together [18], the presence of significant gray 
matter changes only in patients with long disease duration, 
when the added value as compared with clinical evaluation 
is limited [17] or the need for complex and time-consuming 
processing [19] that is not compatible with a clinical rou-
tine application.
As the diagnosis of PD and APS can be challenging 
when solely based on clinical evaluation, several func-
tional imaging ligands have been developed to improve 
diagnostic accuracy. Using multimodal imaging, i.e., pre-
synaptic dopamine SPECT imaging, postsynaptic raclo-
pride PET or IBZM SPECT, and myocardial 123I-meta-
iodobenzylguanidine (MIBG) scintigraphy can be useful 
in distinguishing PD from APS, especially in atypical 
presentations and early cases. However, this requires per-
forming several scans and exposing the patients to a sig-
nificant amount of radiation, not to mention major costs 
for the medical facility. With the present study, we have 
been able to show accurate classification of PD and APS 
solely based on striatal semiquantitative DaT SPECT, a 
molecular imaging technique widely available in clinical 
practice and the only approved one by both 6FDA and 
European medical agencies for the distinction of PS from 
non-degenerative forms of parkinsonism and tremor. The 
tentative flowchart proposed on Fig. 4, although simpli-
fied and subject to many exceptions, may guide clinicians 
in the differential diagnosis of PS and non-degenerative 
forms of parkinsonism.
The strengths of our study comprise the large cohort of 
subjects with PS (including almost 300 subjects with PD 
and 90 with APS) who were scanned at a single-center 
level with the same acquisition and processing SPECT 
protocol. In addition, the semiquantitative parameters 
used for SVM classification are easily obtainable by any 
nuclear medicine facility. This could ensure replication 
of the present results in other centers and potential daily 
utilization of the highest SPECT predictors in helping to 
disentangle the various forms of PS. Our study also has 
limitations. First, diagnosis is based on clinical diagnos-
tic criteria and most cases have not been confirmed by 
autopsy. However, we are confident that the retrospective 
nature of the study, the assessment of DaT SPECT by two 
unrelated visual and semiquantitative methods and a thor-
ough follow-up by neurologists specialized in movement 
disorders (mean follow-up 4.4 years) should have ensured 
a low rate of diagnostic misattribution. Second, our CTL 
group is not based on healthy asymptomatic subjects, but 
on patients with clinically diagnosed non-degenerative 
forms of parkinsonism or tremor (mainly ET, DIP and 
PP). Again, the retrospective design of the study and the 
long follow-up for most cases allowed us to include only 
subjects whose condition did not convert into any neu-
rodegenerative process over time and who presented a 
normal DaT SPECT. In addition, we were not able to 
obtain a clinical rating scale of motor severity (e.g., 
MDS-UPDRS-III) for every included subject. Using such 
a clinical scale as a covariate (instead of disease duration) 
would possibly have allowed an even better performance 
of SVM-based discrimination between PD and atypical 
conditions. Finally, the same SPECT machine and gamma 
camera have been used for all subjects included in the 
present study. This certainly helped in obtaining homo-
geneous uptake values. However, despite 6-month peri-
odic quality controls ensured that scanner sensitivity was 
globally stable, we cannot fully exclude that time slightly 
affected the image quality.
In conclusion, our results indicate that semiquantitative 
striatal 123I-FP-CIT SPECT assessment provides a promis-
ing approach to distinguish reasonably well CTL, PD and 
APS, and that, in combination with SVM, a satisfactory 
classification can be obtained at the individual level. SVM 
and other computer-aided classification systems represent 
a valuable tool to assist the clinician’s daily evaluation of 
patients with PS.
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